논문 상세보기

Production of Transgenic Mini-Pigs with Human Cytomegalovirus Protein US11 by Somatic Cell Nuclear Transfer

  • 언어ENG
  • URLhttps://db.koreascholar.com/Article/Detail/191596
모든 회원에게 무료로 제공됩니다.
발생공학 국제심포지엄 및 학술대회 (International Symposium on Developmental Biotechnology)
한국동물번식학회 (The Korean Society of Animal Reproduction)
초록

Pigs may be considered as a suitable organ source for its characteristics in xenotransplantation if significant immunological barriers can be overcome. However, xenograft could be rejected by T cells, especially CD8+ cytotoxic T lymphocytes (CTL)-mediated response, because these elements show great cytotoxicity against xenograft by recognizing Swine Leukocyte Antigen (SLA)-I. Human cytomegalovirus (HCMV) encodes unique short (US) 11 gene, which interferes with cellular immune responses by inducing rapid degradation of newly synthesized heavy chains (HC) of MHC class I from endoplasmic reticulum (ER) to the cytosol. In this study we established two US11 clonal cell lines by transfection into minipig fetal fibroblasts and confirmed the integration of US11 gene by PCR and FISH. The reduction of Swine Leukocyte Antigen (SLA)-I which was expressed on the cell surface by US11 was also detected by flow cytometry assay. The level (14.6 % to 21.2%) of SLA-I expression in US11 clonal cell lines was decreased relative to the control. The reconstructed embryos were produced with these clonal cells and transferred to nine surrogate gilts. Ultrasound examination of recipient surrogates on days 35 after embryo transfer confirmed established pregnancies in two recipients. One recipient delivered one piglet with normal birth weight. PCR analysis revealed that transgene vector was integrated in the offspring genome. Transgene-expression analysis and CTL assay are currently underway. The present results show that transgenic pig was produced with US11 cDNA for controlling cell-mediated rejection. This result indicated that grafts of transgenic pigs expressing human cytomegalovirus protein US11 could control the cellular immune response to xenografts, and create a window of opportunity to facilitate xenograft survival. This research was supported by the BioGreen 21 Program (#20110301-061-541- 001-05-00), Rural Development Administration, Republic of Korea.

저자
  • Young-Chul Park(MGEN, Inc.)
  • Ki-Myung Choi(MGEN, Inc.)
  • Yun-Jin Yun(MGEN, Inc.)
  • Da-Young Park(MGEN, Inc.)
  • Jae-Goo Seol(MGEN, Inc.)